Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2014

Open Access 01-12-2014 | Study protocol

Selective internal radiotherapy (SIRT) versus transarterial chemoembolization (TACE) for the treatment of intrahepatic cholangiocellular carcinoma (CCC): study protocol for a randomized controlled trial

Authors: Roman Kloeckner, Christian Ruckes, Kai Kronfeld, Marcus Alexander Wörns, Arndt Weinmann, Peter Robert Galle, Hauke Lang, Gerd Otto, Waltraud Eichhorn, Mathias Schreckenberger, Christoph Dueber, Michael Bernhard Pitton

Published in: Trials | Issue 1/2014

Login to get access

Abstract

Background

Cholangiocellular carcinoma is the second most common primary liver cancer after hepatocellular carcinoma. Over the last 30 years, the incidence of intrahepatic cholangiocellular carcinoma has risen continuously worldwide. Meanwhile, the intrahepatic cholangiocellular carcinoma has become more common than the extrahepatic growth type and currently accounts for 10-15% of all primary hepatic malignancies. Intrahepatic cholangiocellular carcinoma is typically diagnosed in advanced stages due to late clinical symptoms and an absence of classic risk factors. A late diagnosis precludes curative surgical resection. There is evidence that transarterial chemoembolization leads to better local tumor control and prolongs survival compared to systemic chemotherapy. New data indicates that selective internal radiotherapy, also referred to as radioembolization, provides promising results for treating intrahepatic cholangiocellular carcinoma.

Methods/Design

This pilot study is a randomized, controlled, single center, phase II trial. Twenty-four patients with intrahepatic cholangiocellular carcinoma will be randomized in a 1:1 ratio to receive either chemoembolization or radioembolization. Randomization will be stratified according to tumor load. Progression-free survival is the primary endpoint; overall survival and time to progression are secondary endpoints. To evaluate treatment success, patients will receive contrast enhanced magnetic resonance imaging every 3 months.

Discussion

Currently, chemoembolization is routinely performed in many centers instead of systemic chemotherapy for treating intrahepatic cholangiocellular carcinoma confined to the liver. Recently, radioembolization has been increasingly applied to cholangiocellular carcinoma as second line therapy after TACE failure or even as an alternative first line therapy. Nonetheless, no randomized studies have compared radioembolization and chemoembolization. Considering all this background information, we recognized a strong need for a randomized controlled trial (RCT) to compare the two treatments. Therefore, the present protocol describes the design of a RCT that compares SIRT and TACE as the first line therapy for inoperable CCC confined to the liver.

Trial registration

ClinicalTrials.gov, Identifier: NCT01798147, registered 16th of February 2013.
Appendix
Available only for authorised users
Literature
1.
2.
Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL: Cholangiocarcinoma - a spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996, 224: 463-473.CrossRefPubMedPubMedCentral
3.
Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, Khan SA, Elliott P, Thomas HC: Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998. Gut. 2001, 48: 816-820.CrossRefPubMedPubMedCentral
4.
Patel T: Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001, 33: 1353-1357.CrossRefPubMed
5.
Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD: Cholangiocarcinoma. Lancet. 2005, 366: 1303-1314.CrossRefPubMed
6.
7.
Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA: Risk factors of intrahepatic cholangiocarcinoma in the United States: a case–control study. Gastroenterology. 2005, 128: 620-626.CrossRefPubMed
8.
Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Loof L, Danielsson A, Hultcrantz R, Lindgren S, Prytz H, Sandberg-Gertzen H, Almer S, Granath F, Broome U: Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 2002, 36: 321-327.CrossRefPubMed
9.
Farrant JM, Hayllar KM, Wilkinson ML, Karani J, Portmann BC, Westaby D, Williams R: Natural-history and prognostic variables in primary sclerosing cholangitis. Gastroenterology. 1991, 100: 1710-1717.PubMed
10.
Chen MF, Jan YY, Wang CS, Hwang TL, Jeng LB, Chen SC, Chen TJ: A reappraisal of cholangiocarcinoma in patient with hepatolithiasis. Cancer. 1993, 71: 2461-2465.CrossRefPubMed
11.
Kubo S, Kinoshita H, Hirohashi K, Hamba H: Hepatolithiasis associated with cholangiocarcinoma. World J Surg. 1995, 19: 637-641.CrossRefPubMed
12.
Lesurtel N, Regimbeau JM, Fargesa O, Colombat M, Sauvanet A, Beighiti J: Intrahepatic cholangiocarcinoma and hepatolithiasis: an unusual association in Western countries. Eur J Gastroenterol Hepatol. 2002, 14: 1025-1027.CrossRefPubMed
13.
Hewitt PM, Krige JEJ, Bornman PC, Terblanche J: Choledochal cysts in adults. Br J Surg. 1995, 82: 382-385.CrossRefPubMed
14.
Lipsett PA, Pitt HA, Colombani PM, Boitnott JK, Cameron JL: Choledochal cyst disease - a changing pattern of presentation. Ann Surg. 1994, 220: 644-652.CrossRefPubMedPubMedCentral
15.
Sorensen HT, Friis S, Olsen JH, Thulstrup M, Mellemkjaer L, Linet M, Trichopoulos D, Vilstrup H, Olsen J: Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology. 1998, 28: 921-925.CrossRefPubMed
16.
Donato F, Gelatti U, Tagger A, Favret M, Ribero ML, Callea F, Martelli C, Savio A, Trevisi P, Nardi G: Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case–control study in Italy. Cancer Causes Control. 2001, 12: 959-964.CrossRefPubMed
17.
Lee CH, Chang CJ, Lin YJ, Yeh CN, Chen MF, Hsieh SY: Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma. Br J Cancer. 2009, 100: 1765-1770.CrossRefPubMedPubMedCentral
18.
Yamamoto S, Kubo S, Hai S, Uenishi T, Yamamoto T, Shuto T, Takemura S, Tanaka H, Yamazaki O, Hirohashi K, Tanaka T: Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Sci. 2004, 95: 592-595.CrossRefPubMed
19.
DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, Choti MC, Yeo CJ, Schulick RD: Cholangiocarcinoma - thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007, 245: 755-762.CrossRefPubMedPubMedCentral
20.
21.
Bloom CM, Langer B, Wilson SR: Role of US in the detection, characterization, and staging of cholangiocarcinoma. Radiographics. 1999, 19: 1199-1218.CrossRefPubMed
22.
Slattery JM, Sahani DV: What is the current state-of-the-art imaging for detection and staging of cholangiocarcinoma?. Oncologist. 2006, 11: 913-922.CrossRefPubMed
23.
Robledo R, Muro A, Prieto ML: Extrahepatic bile duct carcinoma: US characteristics and accuracy in demonstration of tumors. Radiology. 1996, 198: 869-873.CrossRefPubMed
24.
Zhang Y, Uchida M, Abe T, Nishimura H, Hayabuchi N, Nakashima Y: Intrahepatic peripheral cholangiocarcinoma: comparison of dynamic CT and dynamic MRI. J Comput Assist Tomogr. 1999, 23: 670-677.CrossRefPubMed
25.
Schwartz LH, Coakley FV, Sun Y, Blumgart LH, Fong YM, Panicek DM: Neoplastic pancreaticobiliary duct obstruction: evaluation with breath-hold MR cholangiopancreatography. Am J Roentgenol. 1998, 170: 1491-1495.CrossRef
26.
Manfredi R, Barbaro B, Masselli G, Vecchioli A, Marano P: Magnetic resonance imaging of cholangiocarcinoma. Semin Liver Dis. 2004, 24: 155-164.CrossRefPubMed
27.
Choi BI, Lee JM, Han JK: Imaging of intrahepatic and hilar cholangiocarcinoma. Abdom Imaging. 2004, 29: 548-557.PubMed
28.
Lee JW, Han JK, Kim TK, Kim YH, Choi BI, Han MC, Suh KS, Kim SW: CT features of intraductal intrahepatic cholangiocarcinoma. Am J Roentgenol. 2000, 175: 721-725.CrossRef
29.
Oh SW, Yoon YS, Shin SA: Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea national health insurance corporation study. J Clin Oncol. 2005, 23: 4742-4754.CrossRefPubMed
30.
He P, Shi JS, Chen WK, Wang ZR, Ren H, Li H: Multivariate statistical analysis of clinicopathologic factors influencing survival of patients with bile duct carcinoma. World J Gastroenterol. 2002, 8: 943-946.CrossRefPubMedPubMedCentral
31.
Miwa S, Miyagawa S, Kobayashi A, Akahane Y, Nakata T, Mihara M, Kusama K, Soeda J, Ogawa S: Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery. J Gastroenterol. 2006, 41: 893-900.CrossRefPubMed
32.
Jan YY, Yeh CN, Yeh TS, Hwang TL, Chen MF: Clinicopathological factors predicting long-term overall survival after hepatectomy for peripheral cholangiocarcinoma. World J Surg. 2005, 29: 894-898.CrossRefPubMed
33.
Ohtsuka M, Ito H, Kimura F, Shimizu H, Togawa A, Yoshidome H, Shimamura F, Shimizu Y, Miyazaki M: Extended hepatic resection and outcomes in intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2003, 10: 259-264.CrossRefPubMed
34.
Uenishi T, Hirohashi K, Kubo S, Yamamoto T, Hamba H, Tanaka H, Kinoshita H: Histologic factors affecting prognosis following hepatectomy for intrahepatic cholangiocarcinoma. World J Surg. 2001, 25: 865-869.CrossRefPubMed
35.
Inoue K, Makuuchi M, Takayama T, Torzilli G, Yamamoto J, Shimada K, Kosuge T, Yamasaki S, Konishi M, Kinoshita T, Miyagawa S, Kawasaki S: Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery. 2000, 127: 498-505.CrossRefPubMed
36.
Yamamoto M, Takasaki K, Yoshikawa T: Extended resection for intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreat Surg. 1999, 6: 117-121.CrossRefPubMed
37.
Madariaga JR, Iwatsuki S, Todo S, Lee RG, Irish W, Starzl TE: Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases. Ann Surg. 1998, 227: 70-79.CrossRefPubMedPubMedCentral
38.
Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz J, Youssef M, Klimstra D, Blumgart LH: Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001, 234: 507-517.CrossRefPubMedPubMedCentral
39.
Lang H, Sotiropoulos GC, Fruhauf NR, Domland M, Paul A, Kind EM, Malago M, Broelsch CE: Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period. Ann Surg. 2005, 241: 134-143.PubMedPubMedCentral
40.
Zgodzinski W, Espat NJ: Radiofrequency ablation for incidentally identified primary intrahepatic cholangiocarcinoma. World J Gastroenterol. 2005, 11: 5239-5240.PubMedPubMedCentral
41.
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J, Investigators ABCT: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010, 362: 1273-1281.CrossRefPubMed
42.
Burger I, Hong K, Schulick R, Georgiades C, Thuluvath P, Choti M, Kamel I, Geschwind JFH: Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol. 2005, 16: 353-361.CrossRefPubMed
43.
Park SY, Kim JH, Yoon HJ, Lee IS, Yoon HK, Kim KP: Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma. Clin Radiol. 2011, 66: 322-328.CrossRefPubMed
44.
Herber S, Otto G, Schneider J, Manzi N, Kummer I, Kanzier S, Schuchmann A, Thies J, Duber C, Pitton M: Transarterial Chemoembolization (TACE) for inoperable intrahepatic Cholangiocarcinoma. Cardiovasc Intervent Radiol. 2007, 30: 1156-1165.CrossRefPubMed
45.
Kuhlmann JB, Euringer W, Spangenberg HC, Breidert M, Blum HE, Harder J, Fischer R: Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol. 2012, 24: 437-443.PubMed
46.
Aliberti C, Benea G, Tilli M, Fiorentini G: Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results. Cardiovasc Intervent Radiol. 2008, 31: 883-888.CrossRefPubMed
47.
Vogl TJ, Naguib NN, Nour-Eldin NE, Bechstein WO, Zeuzem S, Trojan J, Gruber-Rouh T: Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: results and prognostic factors governing treatment success. Int J Cancer. 2012, 131: 733-740.CrossRefPubMed
48.
Salem R, Gilbertsen M, Butt Z, Memon K, Vouche M, Hickey R, Baker T, Abecassis MM, Atassi R, Riaz A, Cella D, Burns JL, Ganger D, Benson AB, Mulcahy MF, Kulik L, Lewandowski R: Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol. 2013, 11: 1358-1365.CrossRefPubMed
49.
Hoffmann RT, Paprottka PM, Schon A, Bamberg F, Haug A, Durr EM, Rauch B, Trumm CT, Jakobs TF, Helmberger TK, Reiser MF, Kolligs FT: Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol. 2012, 35: 105-116.CrossRefPubMed
50.
Riaz A, Lewandowski RJ, Kulik LM, Mulcahy MF, Sato KT, Ryu RK, Omary RA, Salem R: Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol. 2009, 20: 1121-1130.CrossRefPubMed
51.
Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C: Pathologic response and microdosimetry of Y-90 microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004, 60: 1552-1563.CrossRefPubMed
52.
Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, Benson A, Espat J, Bilbao JI, Sharma RA, Thomas JP, Coldwell D: Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007, 68: 13-23.CrossRefPubMed
53.
Kennedy AS, McNeillie P, Dezarn WA, Nutting C, Sangro B, Wertman D, Garafalo M, Liu D, Coldwell D, Savin M, Jakobs T, Rose S, Warner R, Carter D, Sapareto S, Nag S, Gulec S, Calkins A, Gates VL, Salem R: Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys. 2009, 74: 1494-1500.CrossRefPubMed
54.
Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK: Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007, 30: 6-25.CrossRefPubMed
55.
Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R, Investigators PV: Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010, 33: 41-52.CrossRefPubMed
56.
Sacco R, Bargellini I, Bertini M, Bozzi E, Romano A, Petruzzi P, Tumino E, Ginanni B, Federici G, Cioni R, Metrangolo S, Bertoni M, Bresci G, Parisi G, Altomare E, Capria A, Bartolozzi C: Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2011, 22: 1545-1552.CrossRefPubMed
57.
Kettenbach J, Stadler A, Katzler IV, Schernthaner R, Blum M, Lammer J, Rand T: Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Intervent Radiol. 2008, 31: 468-476.CrossRefPubMed
58.
Poon RT, Tso WK, Pang RW, Ng KK, Woo R, Tai KS, Fan ST: A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol. 2007, 5: 1100-1108.CrossRefPubMed
59.
Skowasch M, Schneider J, Otto G, Weinmann A, Woerns MA, Dueber C, Pitton MB: Midterm follow-up after DC-BEAD-TACE of Hepatocellular Carcinoma (HCC). Eur J Radiol. 2012, 81: 3857-3861.CrossRefPubMed
60.
Lencioni R, Llovet JM: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010, 30: 52-60.CrossRefPubMed
Metadata
Title
Selective internal radiotherapy (SIRT) versus transarterial chemoembolization (TACE) for the treatment of intrahepatic cholangiocellular carcinoma (CCC): study protocol for a randomized controlled trial
Authors
Roman Kloeckner
Christian Ruckes
Kai Kronfeld
Marcus Alexander Wörns
Arndt Weinmann
Peter Robert Galle
Hauke Lang
Gerd Otto
Waltraud Eichhorn
Mathias Schreckenberger
Christoph Dueber
Michael Bernhard Pitton
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Trials / Issue 1/2014
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/1745-6215-15-311

Other articles of this Issue 1/2014

Trials 1/2014 Go to the issue

Study protocol

Improving adolescent mental health and resilience through a resilience-based intervention in schools: study protocol for a randomised controlled trial

Study protocol

The feasibility of a randomized controlled trial of esophagectomy for esophageal cancer - the ROMIO (Randomized Oesophagectomy: Minimally Invasive or Open) study: protocol for a randomized controlled trial

Study protocol

Comparing the effect of a decision aid plus patient navigation with usual care on colorectal cancer screening completion in vulnerable populations: study protocol for a randomized controlled trial

Study protocol

Low-level night-time light therapy for age-related macular degeneration (ALight): study protocol for a randomized controlled trial

Study protocol

A pilot study to evaluate the efficacy of adding a structured home visiting intervention to improve outcomes for high-risk families attending the Incredible Years Parent Programme: study protocol for a randomised controlled trial

Research

Exploring recruitment barriers and facilitators in early cancer detection trials: the use of pre-trial focus groups